CBG shows early promise against schizophrenia-like behaviors
Cannabigerol, a minor phytocannabinoid, prevents behavioral changes induced by psychotomimetic drugs.
AI Summary
Cannabigerol (CBG), a non-intoxicating cannabinoid from Cannabis sativa, reduced several schizophrenia-like behavioral changes in male mice. The researchers tested whether CBG could counteract effects produced by d-amphetamine and MK-801, drugs commonly used to model aspects of psychosis in animals.
CBG lessened drug-related disruptions in sensory filtering, movement, social interaction, and recognition memory across different behavioral tests. The benefits appeared at reduced concentrations, leading the authors to describe CBG as a promising candidate for future translational and clinical research. However, these results come from animal experiments and do not show that CBG treats schizophrenia or psychosis in people; the abstract also provides no quantitative results.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Mental Health research papers you might find interesting.
Brain blood-flow reductions in acute anorexia follow a cortical hierarchy
CBD showed limited adaptive-functioning differences versus placebo in boys…
Resilience linked to depression outcomes and THC positivity
Explore More Research
Stay informed about the latest cannabis science.